Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
WATSON LABORATORIES, INC. v. SEBELIUS et al
Case Number:
1:12-cv-01344
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
October 23, 2012
Wash. Judge Won't Stop Actos Generic For Mylan Appeal
Mylan Pharmaceuticals Inc. on Tuesday lost its bid to block Watson Laboratories Inc.'s production of a generic version of diabetes drug Actos while it appeals to the D.C. Circuit a Washington federal judge's Monday order directing the U.S. Food and Drug Administration to immediately approve the generic drug.
-
October 22, 2012
Judge Orders FDA To Approve Watson's Generic Actos
A Washington federal judge on Monday ordered the U.S. Food and Drug Administration to immediately approve Watson Laboratories Inc.'s generic version of Takeda North America Inc. diabetes drug Actos, after Watson accused the FDA of attempting to rob it of a 180-day marketing exclusivity period.
-
August 15, 2012
Watson Sues FDA To Regain Exclusivity For Generic Actos
Generic-drug maker Watson Laboratories Inc. sued the U.S. Food and Drug Administration on Wednesday in Washington federal court, claiming the agency is attempting to rob Watson of a 180-day marketing exclusivity period for a generic version of Takeda North America Inc.'s diabetes drug Actos.